Acute Type A Aortic Dissection During Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor Lenvatinib Therapy.
Journal
Case reports in critical care
Journal Volume
2025
Start Page
Article number 3082479
ISSN
2090-6420
Date Issued
2025
Author(s)
Wu, Jo-Ju
Abstract
A 67-year-old male with hepatocellular carcinoma under lenvatinib therapy suffered from initially back pain and then abdominal pain, dyspnea, and oliguria. Acute type A aortic dissection was diagnosed with point-of-care ultrasound and computed tomography during the admission. Patients treated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have a low but significant risk of aortic dissection. As a newer member of VEGF-TKIs, lenvatinib has a similar or even higher risk of aortic dissection compared to others. Clinicians should take the cardiovascular risk into consideration while prescribing lenvatinib and keep the differential diagnosis of aortic dissection in mind during the therapy.
SDGs
Type
journal article